Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 9/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 7/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 6/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valproic Acid SCHEMBL4551299 | 0.89 | HDAC1 (0.79) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| Ar-42 SCHEMBL2158594 | 0.87 | HDAC1 (0.76) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL673533 | 0.83 | HDAC1 (0.71) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL22570424 | 0.80 | HDAC2 (0.65) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL673562 | 0.76 | HDAC1 (0.82) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL673402 | 0.76 | HDAC6 (1.00) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL5020665 | 0.75 | HDAC1 (1.00) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL674421 | 0.74 | HDAC1 (0.92) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL22040686 | 0.74 | HDAC1 (0.61) | HDAC1HDAC8HDAC6HDAC2HDAC3 | |
| SCHEMBL13153538 | 0.73 | TRPV1 (0.58) | HDAC1HDAC8HDAC6HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115090-B2 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-08-25 | — | — | US | claimed |
| US-8318808-B2 | Zn2+chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | claimed |
| US-20090137679-A1 | ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-05-28 | — | — | US | claimed |
| EP-2040731-A2 | SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER | Merrion Research III Limited (IE) | 2009-04-01 | — | — | EP | claimed |
| WO-2007146234-A2 | SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER | MERRION RESEARCH II LIMITED (IE) | 2007-12-21 | — | — | WO | claimed |
| US-20070292512-A1 | Solid Oral Dosage Form Containing an Enhancer | MERRION RESEARCH II LIMITED (IE) | 2007-12-20 | — | — | US | claimed |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-09-27 | — | — | US | claimed |
| US-20070148228-A1 | Solid oral dosage form containing an enhancer | MERRION RESEARCH I LIMITED (IE) | 2007-06-28 | — | — | US | claimed |
| EP-1696898-A2 | ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | claimed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | claimed |
| US-20240285556-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA | OHIO STATE INNOVATION FOUNDATION | 2024-08-29 | — | — | US | disclosed |
| US-11938105-B1 | Methods and compositions for the treatment of cancer cachexia | OHIO STATE INNOVATION FOUNDATION (US) | 2024-03-26 | — | — | US | disclosed |
| US-11529323-B2 | Methods and compositions for the treatment of cancer cachexia | OHIO STATE INNOVATION FOUNDATION (US) | 2022-12-20 | — | — | US | disclosed |
| CN-105688218-A | Solid pharmaceutical composition with enhancers and methods of preparing thereof | 诺和诺德股份有限公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-102970979-B | Solid pharmaceutical composition with enhancer and preparation method thereof | MERRION RESEARCH III LTD. (IE) | 2016-04-13 | — | — | CN | disclosed |
| US-20070292512-A1 | Solid Oral Dosage Form Containing an Enhancer | MERRION RESEARCH II LIMITED (IE) | 2007-12-20 | — | — | US | disclosed |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070148228-A1 | Solid oral dosage form containing an enhancer | MERRION RESEARCH I LIMITED (IE) | 2007-06-28 | — | — | US | disclosed |
| EP-1696898-A2 | ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292512-A1 | Solid Oral Dosage Form Containing an Enhancer | CEL, SLC10A2, FABP2 | HDAC1 47/4885HDAC8 113/4885HDAC6 66/4885 |
| US-20070225373-A1 | Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase | HDAC1, BAZ2B, HDAC11 | HDAC1 1/4885HDAC8 14/4885HDAC6 13/4885 |
| US-20240285556-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA | HDAC5, HDAC1, HDAC7 | HDAC1 2/4885HDAC8 10/4885HDAC6 9/4885 |
| US-11938105-B1 | Methods and compositions for the treatment of cancer cachexia | HDAC5, HDAC1, HDAC7 | HDAC1 2/4885HDAC8 10/4885HDAC6 9/4885 |
| US-20090137679-A1 | ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors | HDAC1, HDAC9, HDAC3 | HDAC1 1/4885HDAC8 9/4885HDAC6 13/4885 |
| US-11529323-B2 | Methods and compositions for the treatment of cancer cachexia | HDAC5, HDAC1, HDAC7 | HDAC1 2/4885HDAC8 10/4885HDAC6 9/4885 |
| US-20070148228-A1 | Solid oral dosage form containing an enhancer | HDAC5, HDAC4, HDAC7 | HDAC1 7/4885HDAC8 8/4885HDAC6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.